Complete or partial remission · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in complete or partial remission Time frame: 24 weeks to end of treatment compared with oral steroids alone (moderate certainty).
1 finding from 1 review
Relapse · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in relapse Time frame: 24 weeks compared with oral steroids alone (low certainty).
1 finding from 1 review
Adverse events: death · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: death compared with oral steroids alone (low certainty).
1 finding from 1 review
Acute kidney injury · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).
1 finding from 1 review
Adverse events: new‐onset glucose intolerance · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: new‐onset glucose intolerance compared with oral steroids alone (low certainty).
1 finding from 1 review
Complete remission · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in complete remission Time frame: 2 to 6 months compared with oral steroids alone (moderate certainty).
1 finding from 1 review
Complete or partial remission · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in complete or partial remission time frame: 3 to 6 months compared with oral steroids alone (moderate certainty).
1 finding from 1 review
Relapse · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in relapse Time frame: 6 to 12 months compared with oral steroids alone (moderate certainty).
1 finding from 1 review
Adverse effects: diabetes or hyperglycaemia · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in adverse effects: diabetes or hyperglycaemia compared with oral steroids alone (low certainty).
1 finding from 1 review
Adverse effects: obesity or Cushing's Syndrome · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids may leads to lower adverse effects: obesity or Cushing's Syndrome compared with oral steroids alone (low certainty).
1 finding from 1 review
Adverse events: hypertension · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in adverse effects: hypertension compared with oral steroids alone (low certainty).
1 finding from 1 review
Acute kidney injury · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).
1 finding from 1 review
Adverse effects: acne · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids may leads to lower adverse effects: acne compared with oral steroids alone (low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · people with radicular low back pain (not due to spinal stenosis)
1 finding from 1 review
Function (continuous) RDQ‐18 (scale 0–18) · people with non‐radicular low back pain
1 finding from 1 review
Function (dichotomous) RDQ‐18 = 0 · people with non‐radicular low back pain
Systemic corticosteroids showed no clear difference in function (dichotomous) RDQ‐18 = 0 compared with placebo (low certainty).
1 finding from 1 review
Surgery Number of participants who underwent surgery · people with non‐radicular low back pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants who experienced a serious adverse event · people with non‐radicular low back pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants who experienced any adverse event Adverse event regardless of severity · people with non‐radicular low back pain
Systemic corticosteroids may leads to lower participants who experienced any adverse event Adverse event… compared with placebo (low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · people with spinal stenosis
1 finding from 1 review